

MOODY'S

INVESTORS SERVICE

Credit Opinion: Fleury SA

Global Credit Research - 01 Mar 2016

Brazil

Ratings

Category	Moody's Rating
Outlook	Negative
Corporate Family Rating -Dom Curr	Ba2
Senior Unsecured -Dom Curr	Ba2
NSR Corporate Family Rating	Aa2.br
NSR Senior Unsecured	Aa2.br

Contacts

Analyst	Phone
Erick Rodrigues/Sao Paulo	55.11.3043.7300
Dean Diaz/New York City	1.212.553.1653
Marianna Waltz, CFA/Sao Paulo	55.11.3043.7300

Key Indicators

[1]Fleury SA	9/30/2015(L)	12/31/2014	12/31/2013	12/31/2012
Revenue (USD Billion)	\$0.6	\$0.7	\$0.8	\$0.8
EBITA Margin	17.5%	16.6%	14.8%	16.6%
Debt / EBITDA	2.8x	3.2x	3.3x	2.1x
EBITA / Interest	2.1x	2.0x	2.1x	3.4x
RCF / Net Debt	43.4%	18.3%	33.6%	56.8%

[1] All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations. Source: Moody's Financial Metrics

Note: For definitions of Moody's most common ratio terms please see the accompanying [User's Guide](#).

Opinion

Rating Rationale

- Strong and well recognized brands in the local market
- Brazilian recession to pressure operations, but health care industry long term fundamentals remain favorable
- Highly fragmented industry provides room for M&A activity
- Disciplined and successful acquisitions
- Adequate credit metrics and liquidity
- Relative small size when compared to global peers

- Ratings are constrained by Brazil's sovereign ratings

Corporate Profile

Founded in 1926, Fleury is a major provider of high quality diagnostic medicine in Brazil through its Patient Service Centers (83% of gross revenues), operations in Hospitals (14% of gross revenues) and others (3% of gross revenues) business segments. The group has a diversified portfolio of brands that envisages different social classes in six Brazilian states and Distrito Federal. For the last twelve months ended in September 2015, Fleury posted revenues of BRL 1.8 billion (approximately USD 624 million converted by the average exchange rate) and adjusted EBITDA of BRL 528 million (28.6% adjusted EBITDA margin).

SUMMARY RATING RATIONALE

The Ba2 ratings are supported by Fleury's strong and well recognized brand, its market positioning in Brazil, focused on the more resilient higher income level population, and the positive long-term prospects for the Brazilian health care industry, despite the expected deterioration in operating environment as a consequence of the Brazilian recession. The ratings incorporate the improved diversification in terms of branding, consumer's profile and geographic footprint derived from Fleury's 27 acquisitions between 2002 and 2012 and the company's adequate credit metrics and liquidity profile. The ratings are constrained by Brazil's sovereign ratings, the company's small size compared to global peers as well as the fragmented nature of the industry, which provides room for M&A.

DETAILED RATING CONSIDERATIONS

STRONG AND WELL RECOGNIZED BRANDS IN THE LOCAL MARKET

Fleury operates under six brands (Fleury, Clínica Felipe Mattoso, Weinmann, a+, Diagnoson a+ and Labs a+) in six Brazilian states and in Distrito Federal, providing premium and intermediary services for customers ranging from classes A through B. The brands Fleury, Clínica Felipe Mattoso and Weinmann labs enjoy leading positions in the A social class in São Paulo, Rio de Janeiro and Rio Grande do Sul states, some of the most economically robust regions of the country. The Fleury brand is widely recognized by patients and physicians. The national brand "a+" was launched in 2011 as a result of the consolidation process of brands previously acquired. Currently, "a+" operations are present in the six main economic centers in Brazil offering diagnostic services to beneficiaries of intermediary level health plans.

The Fleury brand, which accounted for 50.2% of the company's revenues in the LTM ending September 2015, benefits from the resilience of the consumption patterns of the higher income level population, which confers defensive characteristics to Fleury's business model. This is particularly important in the current challenging economic environment in Brazil, where economic recession is quickly driving unemployment rates higher and reducing the total number of health plan beneficiaries.

Unlike in the US and other markets, the choice of a health care provider in Brazil is usually determined by the patient and procedures are performed outside of hospitals and medical consultations. In Moody's view, Fleury's successful branding strategy provides a competitive advantage to the company during the patient's decision making process. The company's wide coverage and integrated solution for physicians also contribute to its strong market position in Brazil.

BRAZILIAN RECESSION TO PRESSURE OPERATIONS, BUT HEALTH CARE INDUSTRY LONG TERM FUNDAMENTALS REMAIN FAVORABLE

The long-term prospects for the Brazilian healthcare industry remain favorable, but contrast with the challenges related to a rising unemployment rate and a decline in total health plan beneficiaries, which impacts especially the lower income job levels. Until September 2015, the number of health plan beneficiaries decreased by 436 thousand as a result of an acute macroeconomic contraction in Brazil and it was the first drop observed since 2004. In the same period almost 730 thousand formal job positions closed in the country, and in the whole year of 2015, 1.5 million jobs were closed. Over the last several years, the increase in the population's average income level led to a gradual growth in private health spending and, according to Datafolha, health plans are the third consumption priority of Brazilians, lagging behind only education and housing. About 15 million net additions to health plans were done between 2005 and 2013, as a consequence of the 13.5 million jobs created in the same period. Although health expenditures tend to be relatively resilient to economic cycles, the crises will pressure the sector operations as we expect further contraction of the jobs market. We see Fleury's brands as more resilient given the high level of service and brand recognition, focused mainly on the higher income level customers, which

should temper the impact of the economic slowdown in the company's operating performance.

In the long-term the population aging will support an increased demand for health care services in Brazil. According to the Brazilian Institute of Geography and Statistics - IBGE, the proportion of Brazilians aged 60 years or older should reach 30% by 2050 (or 19.2 million inhabitants) from 13% in 2013. Also, the private health plan segment is still under-penetrated in the country, especially when compared to international standards. By September 2015, only 26% of the Brazilian population had a health plan contracted, while in developed economies the penetration rate reached 37% in the same period, according to ANS - National Health Agency. It is noteworthy that the individual penetration rate is higher than Brazil's average in more developed states such as São Paulo (45%) and Rio de Janeiro (37%), where Fleury has a particularly strong presence.

HIGHLY FRAGMENTED INDUSTRY PROVIDES ROOM FOR M&A ACTIVITIES

The private health care sector in Brazil is very fragmented and has no dominant player. There are currently more than five thousand health care service centers that serve private health plans in the country. We believe that, in a fragmented industry, larger players like Fleury are in a more advantageous situation and have broader bargaining power when dealing with health insurance providers and hospitals. Negotiations with health insurance providers are usually made once a year, and consist of the price adjustment to be implemented by the health care service providers.

Also, under this scenario, further industry consolidation is expected, especially involving larger and capitalized players such as Fleury. However, the assigned ratings incorporate our expectations that Fleury will conduct any future acquisition in a prudent manner in order to preserve its creditworthiness.

DISCIPLINED AND SUCCESSFUL ACQUISITIONS

Acquisitions were a key growth strategy for Fleury in the recent past and we believe the company will continue to pursue opportunistic acquisitions to further consolidate its position in the Brazilian market. Although M&A activity can entail integration challenges, higher working capital and investment needs, we recognize that Fleury has so far managed well its acquisitions. Originally, the Fleury group targeted the A social class in the state of Sao Paulo. Through acquisitions, it managed to diversify its revenues, both in terms of customer base and geographic footprint. Currently, Fleury is present in six Brazilian states and Distrito Federal and its portfolio of brands covers social classes A and B. Despite the acquisitions, the company's growth has been mainly organic-driven, with most of the group's revenues increase coming from its existing operations - with the exception of the Labs D'Or deal, a BRL 1.2 billion acquisition announced in 2011.

The Labs D'Or acquisition (i) increased Fleury's presence in the state of Rio de Janeiro; (ii) brought business opportunities through the alliance with Rede D'Or and Sao Luiz Hospitals; (iii) diversified the company's product portfolio mix, with an increase in imaging diagnosis and hospital services; and (iv) turned Fleury into a bigger player, with higher market strength and broader bargaining power.

Since 2013, Fleury did not announce any acquisition and focused on business integration and cost efficiencies to recover profitability.

ADEQUATE CREDIT METRICS AND LIQUIDITY

In the last twelve months ended September 2015, Fleury's adjusted leverage of 2.8x compared favorably to similarly rated companies. During 2013 and 2014 the company faced some headwinds and margins were negatively impacted by: (i) operational adjustments and integration costs in Rio de Janeiro; (ii) the early stage of new a+ brand labs, which have not yet reached maturity; (iii) the company's strategy to adequate its service offering by focusing on more profitable clients and on cost synergies; and, lastly, (iv) inflationary cost pressures. Following those pressures, the adjustments and strategic focus improved Fleury's profitability already in 2015, but now the risks come from the environment Fleury is inserted in and margins will be challenged by a contracting market, rising inflation (as approximately 51% of Fleury's costs are related to labor), and currency depreciation (which will increase dollar denominated costs, about 10% of total). Still, we recognize Fleury's track record of efficiently passing-through some of the costs increases.

Even with the increased cost pressure we estimate Fleury will be able to sustain operating margins fairly close to current levels in the next 12 months. We estimate top line will still benefit from volume and price increases and Fleury will continue to benefit from steering actions taken in 2013 and 2014. Going forward, the company will benefit from its position within the A and B social classes in Brazil for whom health care spending is more resilient. For the LTM ending September 2015, Fleury's adjusted EBITDA margin reached 28.6%, up from a low of 26% at

the end of 2013, reflecting the operational adjustments made by the company in the last two years. In the 3Q15, adjusted EBITDA margin reached 30.3% and Fleury posted revenues/m² of BRL 4.3, the highest level since 2011, with same store sales increasing 6.9% in 3Q15 versus 3Q14.

In October 2014, Fleury raised a BRL 102 million loan with FINEP (public company linked to the Ministry of Science and Technology) to fund projects that will improve productivity and level of service, thus supporting the expansion of existing premium brands. The loan has a 8-year term, grace period of 2 years and annual interest payment of 4%. In addition to the FINEP line, Fleury's indebtedness comprises two debentures totaling BRL 926 million at the end of September 2015. The debentures are already been amortized, and the next relevant installment (of BRL 150 million plus accrued interests) is due in the 4Q16. Pro forma to the next payment and the one made in 4Q15, Fleury's adjusted leverage would decline to 2.4x, providing the company more room under financial metrics.

The company's liquidity continues to be adequate and debt maturities remain concentrated in the long-term. As of September 2015, cash position of BRL 617 million was sufficient to cover reported short term debt by 7.7 times and corresponded to 59% of total reported debt. At the current margin level, Fleury's cash flow from operations should be sufficient to cover non-discretionary capex and its dividend pay-out orientation, considering the 1H15 distribution of 35% of net income. Accordingly, we expect Fleury to generate positive free cash flow, which should be used together with a portion of its cash balance to meet upcoming debt maturities.

RELATIVE SMALL SIZE WHEN COMPARED TO GLOBAL PEERS

Although acquisitions have increased Fleury's size, the company remains relatively small when compared to global peers, with annual net revenues of BRL 1.8 billion as of LTM September 2015. In Moody's view, larger companies are often better able to realize economies of scale, to benefit from broader access to potential customers and to have more access to capital markets, if needed. Nevertheless, Fleury's ratings incorporate its position as one of the largest providers of diagnostic medicine in Brazil.

RATINGS ARE CONSTRAINED BY BRAZIL'S SOVEREIGN RATING

Fleury generates 100% of its revenues in the local market and, although it operates in a resilient segment, one of its main growth drivers is the creation of formal jobs, which has deteriorated significantly in the last year, and is expected to remain weak at least until the end of 2016. In our view, rising unemployment and inflation, coupled with reduced additions to health plans could pressure Fleury's operating performance. Accordingly, Fleury's ratings are unlikely to stand above Brazil's sovereign rating.

Corporate Governance

Fleury is a public owned company listed in the São Paulo Stock Exchange, BM&F Bovespa. Currently, 39.9% of its shares are in free float and the company is part of Bovespa's Novo Mercado, the level with the highest standards of corporate governance in Brazil. The largest shareholders are the partner doctors via their indirect stake, through Integritas, of 12.0% and direct stake of 16.3%, linked to the shareholders agreement. In September 2015, the partner doctors sold 13% of Fleury's total shares to Advent International (unrated) private equity firm, through the sale of Core Participações ("Core", unrated) shares. The transaction resulted in the election of a new Board of Directors, which is now composed of 10 members, of which 3 are nominated by the partner doctors, 2 by Advent, 2 by Bradseg (Fleury's second largest shareholder with 16.4% of total shares) and the remaining 3 as independent members. There were no changes to Fleury's senior management as a result of the transaction. In Moody's opinion, the implementation of a permanent fiscal committee and formal financial policies regarding leverage target and minimum liquidity would be positive for Fleury's corporate governance practices.

Rating Outlook

The negative outlook on Fleury's ratings mirrors the negative outlook for Brazil's sovereign ratings.

What Could Change the Rating - Up

Although unlikely in the short term, an upgrade would depend on an upgrade of Brazil's sovereign rating. Positive pressure on the ratings would also require Fleury to continue generating consistent organic growth, while pursuing its expansion strategy, and to maintain stable profitability levels even during the foreseen market deterioration.

What Could Change the Rating - Down

The ratings could be lowered if the company fails to deliver organic growth or to maintain EBITDA margins near its

current level. The ratings could also come under pressure if leverage ratio remains above 3.5x, if free cash flow remains negative on a consistent basis or if liquidity deteriorates. Additional negative actions on Brazil's sovereign ratings would also trigger a downgrade of Fleury's ratings.

Other Considerations

MAPPING TO THE RATING METHODOLOGY

Fleury's grid-indicated rating under Moody's Business and Consumer Service Industry Rating Methodology maps to a "Ba2" rating, in line with assigned ratings. Prospectively, Moody's 12-18 month forward view also maps to a "Ba2" rating.

Rating Factors

Fleury SA

Business and Consumer Service Industry Grid [1][2]	Current LTM 9/30/2015		[3]Moody's 12-18 Month Forward ViewAs of 2/22/2016	
Factor 1 : Scale (20%) a) Revenue (USD Billion)	Measure \$0.6	Score B	Measure \$0.5 - \$1	Score B
Factor 2 : Business Profile (20%) a) Demand Characteristics b) Competitive Profile	Baa Ba	Baa Ba	Baa Ba	Baa Ba
Factor 3 : Profitability (10%) a) EBITA Margin	17.5%	Ba	15% - 20%	Ba
Factor 4 : Leverage and Coverage (40%) a) Debt / EBITDA b) EBITA / Interest c) RCF / Net Debt	2.8x 2.1x 43.4%	Baa B A	2x - 3x 1x - 3x 25% - 40%	Baa B Baa
Factor 5 : Financial Policy (10%) a) Financial Policy	Ba	Ba	Ba	Ba
Rating: a) Indicated Rating from Grid b) Actual Rating Assigned		Ba2		Ba2 Ba2

[1] All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations. [2] As of 9/30/2015(L); Source: Moody's Financial Metrics [3] This represents Moody's forward view; not the view of the issuer; and unless noted in the text, does not incorporate significant acquisitions and divestitures

This publication does not announce a credit rating action. For any credit ratings referenced in this publication, please see the ratings tab on the issuer/entity page on <http://www.moody's.com> for the most updated credit rating action information and rating history.

MOODY'S
INVESTORS SERVICE

© 2016 Moody's Corporation, Moody's Investors Service, Inc., Moody's Analytics, Inc. and/or their licensors and affiliates (collectively, "MOODY'S"). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY'S INVESTORS SERVICE, INC. AND ITS RATINGS AFFILIATES ("MIS") ARE MOODY'S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES,

CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND CREDIT RATINGS AND RESEARCH PUBLICATIONS PUBLISHED BY MOODY'S ("MOODY'S PUBLICATIONS") MAY INCLUDE MOODY'S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES. MOODY'S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL, FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS AND MOODY'S OPINIONS INCLUDED IN MOODY'S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY'S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. CREDIT RATINGS AND MOODY'S PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND CREDIT RATINGS AND MOODY'S PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. NEITHER CREDIT RATINGS NOR MOODY'S PUBLICATIONS COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY'S ISSUES ITS CREDIT RATINGS AND PUBLISHES MOODY'S PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE. MOODY'S CREDIT RATINGS AND MOODY'S PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS OR MOODY'S PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT.

All information contained herein is obtained by MOODY'S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "AS IS" without warranty of any kind. MOODY'S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY'S considers to be reliable including, when appropriate, independent third- party sources. However, MOODY'S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing the Moody's Publications.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by MOODY'S.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY SUCH RATING OR OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY'S IN ANY FORM OR MANNER WHATSOEVER.

Moody's Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody's Corporation ("MCO").

hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody's Investors Service, Inc. have, prior to assignment of any rating, agreed to pay to Moody's Investors Service, Inc. for appraisal and rating services rendered by it fees ranging from \$1,500 to approximately \$2,500,000. MCO and MIS also maintain policies and procedures to address the independence of MIS's ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold ratings from MIS and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moody.com under the heading "Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy."

Additional terms for Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of MOODY'S affiliate, Moody's Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody's Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY'S that you are, or are accessing the document as a representative of, a "wholesale client" and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to "retail clients" within the meaning of section 761G of the Corporations Act 2001. MOODY'S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors. It would be reckless and inappropriate for retail investors to use MOODY'S credit ratings or publications when making an investment decision. If in doubt you should contact your financial or other professional adviser.

Additional terms for Japan only: Moody's Japan K.K. ("MJKK") is a wholly-owned credit rating agency subsidiary of Moody's Group Japan G.K., which is wholly-owned by Moody's Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody's SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJKK or MSFJ (as applicable) for appraisal and rating services rendered by it fees ranging from JPY200,000 to approximately JPY350,000,000. MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.